Home CRSP
55.51
  Price0.43%   +0.24
(After Hours: 55.50 -0.010 -0.02% )
loading

CRISPR Therapeutics AG (CRSP) Latest News

Feb-06-23 08:15AM Ready to Buy the Dip? Consider This Gene Editing StockThe Motley Fool
05:55AM 3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%The Motley Fool
Feb-03-23 02:02AM Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?Zacks Investment Research
02:00AM 3 No-Brainer Growth Stocks to Buy in 2023The Motley Fool
Feb-03-23 12:10PM Why Editas Medicine's Shares Jumped This WeekThe Motley Fool
06:15AM Is Editas Medicine Stock a Buy Now?The Motley Fool
Feb-03-23 03:52AM Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?Zacks Investment Research
Feb-01-23 01:03AM Analyst Initiates Coverage On This Peer Lagging Gene-Editing StockBenzinga
09:54AM Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'Benzinga
Jan-31-23 10:00AM 3 Things About CRISPR Therapeutics That Smart Investors KnowThe Motley Fool
Jan-27-23 06:50AM 3 Healthcare Stocks to Buy and Hold for the Next 10 YearsThe Motley Fool
01:28AM Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2022 UpdateSeeking Alpha
Jan-19-23 10:07AM CRISPR Therapeutics Stock: Bull vs. BearThe Motley Fool
Jan-18-23 06:00AM 5 Reasons to Buy Vertex Pharmaceuticals NowThe Motley Fool
Jan-16-23 05:30AM 2 Stocks Down More Than 25% to Buy Right NowThe Motley Fool
Jan-13-23 05:30AM 5 Potentially Explosive Stocks to Buy in 2023The Motley Fool
Jan-12-23 06:23AM More Likely to 5X First: CRISPR Therapeutics vs. InModeThe Motley Fool
12:15PM Prime Medicine 'Crispr 3.0' Vs. Crispr TherapeuticsSeeking Alpha
Jan-11-23 09:37AM 2 Growth Stocks You May Regret not Buying Right NowThe Motley Fool
05:30AM Can Cathie Wood Bounce Back in 2023?The Motley Fool
Jan-11-23 05:10AM 2 Supercharged Stocks to Buy Right Now That Could Soar in 2023The Motley Fool
Jan-06-23 08:45AM 2 Under-the-Radar Biotech Stocks to Buy in 2023The Motley Fool
Jan-05-23 10:01AM Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023Benzinga
08:00AM Expert Ratings for CRISPR TherapeuticsBenzinga
Jan-04-23 11:48AM Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'Benzinga
06:00AM Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over TimeThe Motley Fool
Dec-30-22 10:07AM 1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)The Motley Fool
Dec-29-22 10:15AM 2 Cathie Wood Stocks to Buy and Hold Through 2023 and BeyondThe Motley Fool
05:52AM 5 Unstoppable Trends to Invest $5,000 in for 2023The Motley Fool
Dec-27-22 10:20AM Could CRISPR Therapeutics Help You Become a Millionaire?The Motley Fool
06:15AM Is Vertex Pharmaceuticals a Buy?The Motley Fool
Dec-24-22 08:07AM After Doubling in the Past 6 Months, Is This Stock a Buy?The Motley Fool
Dec-22-22 09:35AM 2 No-Brainer Biotech Stocks to Buy Right NowThe Motley Fool
06:19AM 3 Cathie Wood Stocks That Could Make Big Comebacks in 2023The Motley Fool
Dec-21-22 09:45AM 3 Growth Stocks That Are Screaming Buys in DecemberThe Motley Fool
Dec-19-22 08:30AM CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business DevelopmentGlobeNewswire Inc.
Dec-18-22 06:00AM Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen StockThe Motley Fool
Dec-17-22 09:15AM 3 Beaten-Down Stocks That Could Explode Higher in 2023The Motley Fool
Dec-15-22 10:07AM 3 Growth Stocks With More Potential Than Any CryptocurrencyThe Motley Fool
Dec-13-22 11:01AM Vertex (VRTX) to Start Clinical Study on mRNA-based CF TherapyZacks Investment Research
Dec-12-22 10:00AM CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®GlobeNewswire Inc.
Dec-11-22 05:52AM 3 Red-Hot Stocks That Could Continue to Beat the MarketThe Motley Fool
Dec-09-22 09:45AM Want to Be Ready For a New Bull Market? Do These 3 Things SoonThe Motley Fool
09:00AM 2 Growth Stocks That Could Help Set You Up for LifeThe Motley Fool
Dec-09-22 06:00AM 5 Best Bargain Stocks to Buy Before 2023The Motley Fool
Dec-08-22 10:15AM 3 Revolutionary Stocks I'd Buy Right Now Without HesitationThe Motley Fool
09:20AM Is CRISPR Therapeutics a Buy?The Motley Fool
Dec-08-22 06:30AM 2 Unstoppable Growth Stocks to Buy in 2022 and BeyondThe Motley Fool
Dec-07-22 08:53AM 3 Fierce Stocks That Are Screaming Buys in DecemberThe Motley Fool
Dec-06-22 10:00AM Is It Too Late to Buy Vertex Pharmaceuticals Stock?The Motley Fool
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:    |  Volume (24h):